Not finding it? Sign in to also search OpenAlex live.
-
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome2020 Journal of the American College of Cardiology article Medicine Lipoproteins and Cardiovascular Health Open access cited by 1 patent
Vera Bittner, Michael J. Szarek, Philip E. Aylward, Deepak L. Bhatt, Rafael Díaz, Jay M. Edelberg, +19 more
604citations -
Efficacy and safety of alirocumab in patients with established atherosclerotic vascular disease before the first cardiovascular event: Pooled analysis of phase 3 ODYSSEY studies2025 Journal of clinical lipidology article Medicine Lipoproteins and Cardiovascular Health Open access
Manuel Castro Cabezas, Mattéa Orsini, Lâle Tokgözoğlu, Nikolaus Marx, José Tuñón, Michal Vrablı́k, +3 more
2citations -
Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome2024 Journal of the American College of Cardiology article Medicine Lipoproteins and Cardiovascular Health Open access
Doron Zahger, Gregory G. Schwartz, Weiming Du, Michael J. Szarek, Deepak L. Bhatt, Vera Bittner, +15 more
15citations -
Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome2023 Canadian Journal of Cardiology article Medicine Lipoproteins and Cardiovascular Health Open access
Philippe Gabríel Steg, Michael J. Szarek, Marco Valgimigli, Md. Shahidul Islam, Andreas Michael Zeiher, Deepak L. Bhatt, +12 more
4citations -
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial2020 European Heart Journal article Medicine Lipoproteins and Cardiovascular Health Open access cited by 2 patents
Michael J. Szarek, Vera Bittner, Philip E. Aylward, Marie T. Baccara‐Dinet, Deepak L. Bhatt, Rafael Díaz, +16 more
221citations -
Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes2020 Journal of the American College of Cardiology article Medicine Lipoproteins and Cardiovascular Health Open access
Deepak L. Bhatt, Andrew H. Briggs, Shelby D. Reed, Lieven Annemans, Michael J. Szarek, Vera Bittner, +23 more
64citations -
Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: a report from the ODYSSEY OUTCOMES study2024 Journal of clinical lipidology article Medicine Lipoproteins and Cardiovascular Health Open access
Vera Bittner, Gregory G. Schwartz, Deepak L. Bhatt, Terrance Siang Jin Chua, H. Asita De Silva, Rafael Díaz, +10 more
26citations -
A placebo‐controlled proof‐of‐concept study of alirocumab on postprandial lipids and vascular elasticity in insulin‐treated patients with type 2 diabetes mellitus2020 Diabetes Obesity and Metabolism article Medicine Lipoproteins and Cardiovascular Health Open access
Benjamin Burggraaf, Nadine M. C. Pouw, Salvador Fernández‐Arroyo, Leonie C. van Vark‐van der Zee, Gert‐Jan M. van de Geijn, Erwin Birnie, +6 more
20citations -
Plasma levels of human growth differentiation factor 15 (GDF-15) and their effect of alirocumab on major adverse cardiovascular events and all-cause death after acute coronary syndrome
J. Wouter Jukema, Nicolaas J.M. van Neer, Michael J. Szarek, Christa M. Cobbaert, Vera Bittner, Markus Schwertfeger, +8 more
2citations -
Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial
José Tuñón, Philippe Gabríel Steg, Deepak L. Bhatt, Vera Bittner, Rafael Díaz, Shaun G. Goodman, +11 more
76citations -
Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial2020 European Journal of Preventive Cardiology article Medicine Lipoproteins and Cardiovascular Health Open access
Rafael Díaz, Qian H Li, Deepak L. Bhatt, Vera Bittner, Marie T. Baccara‐Dinet, Shaun G. Goodman, +13 more
58citations -
Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial
Gregory G. Schwartz, Michael J. Szarek, Deepak L. Bhatt, Vera Bittner, Maja Bujas‐Bobanovic, Rafael Díaz, +11 more
47citations -
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation2024 European Heart Journal - Cardiovascular Pharmacotherapy article Medicine Lipoproteins and Cardiovascular Health Open access
Shaun G. Goodman, Philippe Gabríel Steg, Michael J. Szarek, Deepak L. Bhatt, Vera Bittner, Rafael Díaz, +61 more
25citations